إعلان
إعلان
ABCL
AbCellera Biologics Inc. Common Shares
4.12
USDبرعاية
-0.01
-0.36%
٠٨ يناير, ١١:١١ UTC -5
مفتوح
تقارير أرباح ABCL
النسبة الإيجابية المفاجئة
ABCL تفوق 8 من 20 آخر التقديرات.
40%
التقرير التالي
بيانات التقرير القادم
٢٥ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$5.75M
/-$0.18
التغير الضمني من Q3 25 (Revenue/ EPS)
-35.75%
/-5.26%
التغير الضمني من Q4 24 (Revenue/ EPS)
+13.94%
/+63.64%
AbCellera Biologics Inc. Common Shares earnings per share and revenue
On ٠٦ نوفمبر ٢٠٢٥, ABCL reported earnings of -0.19 USD per share (EPS) for Q3 25, missing the estimate of -0.17 USD, resulting in a -10.40% surprise. Revenue reached 8.96 مليون, compared to an expected 6.03 مليون, with a 48.57% difference. The market reacted with a -13.69% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 المحللين forecast an EPS of -0.18 USD, with revenue projected to reach 5.75 مليون USD, implying an نقصان of -5.26% EPS, and نقصان of -35.75% in Revenue from the last quarter.
الأسئلة الشائعة
What were AbCellera Biologics Inc. Common Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, AbCellera Biologics Inc. Common Shares reported EPS of -$0.19, missing estimates by -10.4%, and revenue of $8.96M, 48.57% above expectations.
How did the market react to AbCellera Biologics Inc. Common Shares's Q3 2025 earnings?
The stock price moved down -13.69%, changed from $4.53 before the earnings release to $3.91 the day after.
When is AbCellera Biologics Inc. Common Shares expected to report next?
The next earning report is scheduled for ٢٥ فبراير ٢٠٢٦.
What are the forecasts for AbCellera Biologics Inc. Common Shares's next earnings report?
Based on 10
المحللين, AbCellera Biologics Inc. Common Shares is expected to report EPS of -$0.18 and revenue of $5.75M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان